Annual report of the Patented Medicine Prices Review Board tabled in House of Commons.

Costs grew faster in 2021-2022 than in the previous five years.

Response to agency’s scoping paper encourages industry’s involvement in pricing review.

Once established, agency is expected to take a greater role in Canada’s drug system.

The Patented Medicine Prices Review Board (PMPRB), a federal entity that ensures patented drug prices in Canada are not …

Intellectual property lawyer takes the helm for five-year term.

Minister of Health tables review board’s annual report with the Senate and House of Commons.